Derivation, validation, and proposed thresholds of the Lupus Arthritis and Musculoskeletal Disease Activity (LAMDA) instrument: a cohort study.

Samuel Wood¹, Khaled Mahmoud¹, Philip G Conaghan², Elizabeth M A Hensor², Edward M Vital³

¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.

²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. Electronic address: e.m.vital@leeds.ac.uk.

PubMed DOI

Abstract

BACKGROUND: Outcome measures for lupus arthritis that are not sensitive to change might contribute to misleading results in systemic lupus erythematosus (SLE) trials. We aimed to optimise lupus arthritis assessment by developing a novel composite disease activity measure, derived against ultrasound synovitis and incorporating participant-reported outcomes. METHODS: In this cohort study we derived…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.